Translating Scientific Discoveries Into Medical Practice
NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research.
But it’s a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health.
The NIAID Office of Technology Development (OTD) facilitates collaborative relationships between NIAID investigators and the broader scientific community.
Highlighted Licensing and Collaboration Opportunities
See the complete list of Recent Licensing and Collaboration Opportunities.
Recent Happenings
United States patent US 7,919,301 was issued on April 5, 2011, for recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens. Lead inventors: Peter L. Collins, Ph.D., Laboratory of Infectious Diseases; Brian R. Murphy, M.D., Laboratory of Infectious Diseases (retired)
United States patent US 7,914,788 was issued on March 29, 2011, for monocolonal antibodies against orthopoxviruses. Lead inventors: Suzanne U. Emerson, Ph.D., Laboratory of Infectious Diseases; Bernard Moss, M.D., Ph.D., Laboratory of Viral Diseases; Robert H. Purcell, M.D., Laboratory of Infectious Diseases
NIAID and Queen’s University Belfast signed an RCA for Development of vaginal rings expressing HIV-neutralizing antibodies for use as microbicides. NIAID principal investigator: Gary J. Nabel, M.D., Ph.D., Vaccine Research Center
See the complete list of Technology Development Recent Happenings.
